Intramuscular delivery of a cholera DNA vaccine primes both systemic and mucosal protective antibody responses against cholera

Vaccine

Volumn 27, Issue 29, 2009, Pages 3821-3830

  Xu, Guifang ^a   Wang, Shixia ^a,c   Zhuang, Ling ^b   Hackett, Anthony ^c   Gu, Ling ^b   Zhang, Lu ^a   Zhang, Chunhua ^a   Wang, Hua ^b   Huang, Zuhu ^a   Lu, Shan ^a,c  

^a NANJING MEDICAL UNIVERSITY   (China)

^b Jiangsu Provincial Center for Diseases Prevention and Control   (China)

^c UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

Cholera; DNA vaccine; Mucosal immunity

Indexed keywords

CHOLERA TOXIN B SUBUNIT; CHOLERA VACCINE; DNA VACCINE; INACTIVATED VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CHOLERA; CONTROLLED STUDY; DNA IMMUNIZATION; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; INFECTION PREVENTION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL;

ANIMALS; ANTIBODIES, BACTERIAL; ANTITOXINS; CHOLERA; CHOLERA TOXIN; CHOLERA VACCINES; IMMUNITY, MUCOSAL; INJECTIONS, INTRAMUSCULAR; MICE; MICE, INBRED BALB C; RABBITS; VACCINES, DNA;

EID: 67349246468     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.04.008     Document Type: Article

References (48)

1. Mekalanos J.J., and Sadoff J.C. Cholera vaccines: fighting an ancient scourge. Science 265 September (5177) (1994) 1387-1389
2. Kaper J.B., Morris Jr. J.G., Levine M.M., and Cholera. Clin Microbiol Rev 8 January (1) (1995) 48-86
3. Slauch J., Taylor R., and Maloy S. Survival in a cruel world: how Vibrio cholerae and Salmonella respond to an unwilling host. Genes Dev 11 July (14) (1997) 1761-1774
4. Crowcroft N.S. Cholera: current epidemiology. Commun Dis Rep CDR Rev 4 December (13) (1994) R157-R164
5. WHO. http://ochaonline.un.org/Default.aspx?alias=ochaonline.un.org/zimbabwe. January 3, 2009.
6. Mekalanos J.J., Swartz D.J., Pearson G.D., Harford N., Groyne F., and de Wilde M. Cholera toxin genes: nucleotide sequence, deletion analysis and vaccine development. Nature 306 December (5943) (1983) 551-557
7. Cassel D., and Pfeuffer T. Mechanism of cholera toxin action: covalent modification of the guanyl nucleotide-binding protein of the adenylate cyclase system. Proc Natl Acad Sci USA 75 June (6) (1978) 2669-2673
8. Burrows W. Cholera toxins. Annu Rev Microbiol 22 (1968) 245-268
9. Taylor R.K., Kirn T.J., Bose N., Stonehouse E., Tripathi S.A., Kovac P., et al. Progress towards development of a cholera subunit vaccine. Chem Biodivers 1 July (7) (2004) 1036-1057
10. Sack D.A., Sack R.B., Nair G.B., and Siddique A.K. Cholera. Lancet 363 January (9404) (2004) 223-233
11. Ryan E.T., Dhar U., Khan W.A., Salam M.A., Faruque A.S., Fuchs G.J., et al. Mortality, morbidity, and microbiology of endemic cholera among hospitalized patients in Dhaka, Bangladesh. Am J Trop Med Hyg 63 July-August (1-2) (2000) 12-20
12. Guthmann J.P. Epidemic cholera in Latin America: spread and routes of transmission. J Trop Med Hyg 98 December (6) (1995) 419-427
13. Ryan E.T., and Calderwood S.B. Cholera vaccines. Clin Infect Dis 31 August (2) (2000) 561-565
14. Olsson L., and Parment P.A. Present and future cholera vaccines. Expert Rev Vaccines 5 December (6) (2006) 751-752
15. Levine M.M. Enteric infections and the vaccines to counter them: future directions. Vaccine 24 May (18) (2006) 3865-3873
16. Hill D.R., Ford L., and Lalloo D.G. Oral cholera vaccines: use in clinical practice. Lancet Infect Dis 6 June (6) (2006) 361-373
17. Ryan E.T., Calderwood S.B., and Qadri F. Live attenuated oral cholera vaccines. Expert Rev Vaccines 5 August (4) (2006) 483-494
18. Levine M.M., and Noriega F. A review of the current status of enteric vaccines. PNG Med J 38 December (4) (1995) 325-331
19. Jertborn M., Svennerholm A.M., and Holmgren J. Safety and immunogenicity of an oral recombinant cholera B subunit-whole cell vaccine in Swedish volunteers. Vaccine 10 2 (1992) 130-132
20. Jertborn M., Svennerholm A.M., and Holmgren J. Immunological memory after immunization with oral cholera B subunit-whole-cell vaccine in Swedish volunteers. Vaccine 12 September (12) (1994) 1078-1082
21. Jertborn M., Svennerholm A.M., and Holmgren J. Evaluation of different immunization schedules for oral cholera B subunit-whole cell vaccine in Swedish volunteers. Vaccine 11 10 (1993) 1007-1012
22. Jertborn M., Nordstrom I., Kilander A., Czerkinsky C., and Holmgren J. Local and systemic immune responses to rectal administration of recombinant cholera toxin B subunit in humans. Infect Immun 69 June (6) (2001) 4125-4128
23. Richie E.E., Punjabi N.H., Sidharta Y.Y., Peetosutan K.K., Sukandar M.M., Wasserman S.S., et al. Efficacy trial of single-dose live oral cholera vaccine CVD 103-HgR in North Jakarta, Indonesia, a cholera-endemic area. Vaccine 18 May (22) (2000) 2399-2410
24. Cohen M.B., Giannella R.A., Bean J., Taylor D.N., Parker S., Hoeper A., et al. Randomized, controlled human challenge study of the safety, immunogenicity, and protective efficacy of a single dose of Peru-15, a live attenuated oral cholera vaccine. Infect Immun 70 April (4) (2002) 1965-1970
25. Viret J.F., Dietrich G., and Favre D. Biosafety aspects of the recombinant live oral Vibrio cholerae vaccine strain CVD 103-HgR. Vaccine 22 June (19) (2004) 2457-2469
26. Mekalanos J.J. Live bacterial vaccines: environmental aspects. Curr Opin Biotechnol 5 June (3) (1994) 312-319
27. Levine M.M., Kaper J.B., Herrington D., Losonsky G., Morris J.G., Clements M.L., et al. Volunteer studies of deletion mutants of Vibrio cholerae O1 prepared by recombinant techniques. Infect Immun 56 January (1) (1988) 161-167
28. Levine M.M., Kaper J.B., Herrington D., Ketley J., Losonsky G., Tacket C.O., et al. Safety, immunogenicity, and efficacy of recombinant live oral cholera vaccines, CVD 103 and CVD 103-HgR. Lancet 2 August (8609) (1988) 467-470
29. Viret J.F., Favre D., Wegmuller B., Herzog C., Que J.U., Cryz Jr. S.J., et al. Mucosal and systemic immune responses in humans after primary and booster immunizations with orally administered invasive and noninvasive live attenuated bacteria. Infect Immun 67 July (7) (1999) 3680-3685
30. Holmgren J., Adamsson J., Anjuere F., Clemens J., Czerkinsky C., Eriksson K., et al. Mucosal adjuvants and anti-infection and anti-immunopathology vaccines based on cholera toxin, cholera toxin B subunit and CpG DNA. Immunol Lett 97 March (2) (2005) 181-188
31. Iijima H., Takahashi I., and Kiyono H. Mucosal immune network in the gut for the control of infectious diseases. Rev Med Virol 11 2 (2001) 117-133
32. Wang S., Farfan-Arribas D.J., Shen S., Chou T.H., Hirsch A., He F., et al. Relative contributions of codon usage, promoter efficiency and leader sequence to the antigen expression and immunogenicity of HIV-1 Env DNA vaccine. Vaccine 24 May (21) (2006) 4531-4540
33. Pear W.S., Nolan G.P., Scott M.L., and Baltimore D. Production of high-titer helper-free retroviruses by transient transfection. Proc Natl Acad Sci USA 90 September (18) (1993) 8392-8396
34. Wang S., Zhang C., Zhang L., Li J., Huang Z., and Lu S. The relative immunogenicity of DNA vaccines delivered by the intramuscular needle injection, electroporation and gene gun methods. Vaccine 26 April (17) (2008) 2100-2110
35. Wu J.Y., Wade W.F., and Taylor R.K. Evaluation of cholera vaccines formulated with toxin-coregulated pilin peptide plus polymer adjuvant in mice. Infect Immun 69 December (12) (2001) 7695-7702
36. Sun D.X., Mekalanos J.J., and Taylor R.K. Antibodies directed against the toxin-coregulated pilus isolated from Vibrio cholerae provide protection in the infant mouse experimental cholera model. J Infect Dis 161 June (6) (1990) 1231-1236
37. Revillard J.P., Cozon G., and Czerkinsky C. Oral administration of immunomodulators and the mucosal immune system. Dev Biol Stand 77 (1992) 31-37
38. Wang S., Arthos J., Lawrence J.M., Van Ryk D., Mboudjeka I., Shen S., et al. Enhanced immunogenicity of gp120 protein when combined with recombinant DNA priming to generate antibodies that neutralize the JR-FL primary isolate of human immunodeficiency virus type 1. J Virol 79 June (12) (2005) 7933-7937
39. Wang S., Pal R., Mascola J.R., Chou T.H., Mboudjeka I., Shen S., et al. Polyvalent HIV-1 Env vaccine formulations delivered by the DNA priming plus protein boosting approach are effective in generating neutralizing antibodies against primary human immunodeficiency virus type 1 isolates from subtypes A, B, C, D and E. Virology 350 June (1) (2006) 34-47
40. Lu S. Combination DNA plus protein HIV vaccines. Springer Semin Immunopathol 28 November (3) (2006) 255-265
41. Pal R., Kalyanaraman V.S., Nair B.C., Whitney S., Keen T., Hocker L., et al. Immunization of rhesus macaques with a polyvalent DNA prime/protein boost human immunodeficiency virus type 1 vaccine elicits protective antibody response against simian human immunodeficiency virus of R5 phenotype. Virology 348 May (2) (2006) 341-353
42. Herrmann J.E., Wang S., Zhang C., Panchal R.G., Bavari S., Lyons C.R., et al. Passive immunotherapy of Bacillus anthracis pulmonary infection in mice with antisera produced by DNA immunization. Vaccine 24 July (31-32) (2006) 5872-5880
43. Bansal A., Jackson B., West K., Wang S., Lu S., Kennedy J.S., et al. Multifunctional T-cell characteristics induced by a polyvalent DNA prime/protein boost human immunodeficiency virus type 1 vaccine regimen given to healthy adults are dependent on the route and dose of administration. J Virol 82 July (13) (2008) 6458-6469
44. Wang S., Kennedy J.S., West K., Montefiori D.C., Coley S., Lawrence J., et al. Cross-subtype antibody and cellular immune responses induced by a polyvalent DNA prime-protein boost HIV-1 vaccine in healthy human volunteers. Vaccine 26 February (8) (2008) 1098-1110
45. Beddows S., Schulke N., Kirschner M., Barnes K., Franti M., Michael E., et al. Evaluating the immunogenicity of a disulfide-stabilized, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1. J Virol 79 July (14) (2005) 8812-8827
46. Vaine M., Wang S., Crooks E.T., Jiang P., Montefiori D.C., Binley J., et al. Improved induction of antibodies against key neutralizing epitopes by human immunodeficiency virus type 1 gp120 DNA prime-protein boost vaccination compared to gp120 protein-only vaccination. J Virol 82 August (15) (2008) 7369-7378
47. Hiroi T., Yanagita M., Iijima H., Iwatani K., Yoshida T., Takatsu K., et al. Deficiency of IL-5 receptor alpha-chain selectively influences the development of the common mucosal immune system independent IgA-producing B-1 cell in mucosa-associated tissues. J Immunol 162 January (2) (1999) 821-828
48. Murakami M., and Honjo T. Involvement of B-1 cells in mucosal immunity and autoimmunity. Immunol Today 16 November (11) (1995) 534-539